AtaiBeckley carries the lowest business quality in its peer set — free cash flow burning at over 1,500% of revenue, a 39% revenue contraction, and a near-perfect record of earnings misses — while trading in a confirmed downtrend with heavily bearish options positioning; fundamental and technical conditions need to improve materially before the setup warrants consideration.
Thesis pillars
- Catastrophic Quality Cash Burn→Stable
- Revenue In Sharp Contraction→Stable
- Chronic Earnings Miss Streak→Stable
- +1 more pillar — see the Why tab for full reasoning
AtaiBeckley Inc. (ATAI) Stock Analysis
Breakout setup · Inst Constrain edge
Healthcare · Biotechnology
Sell if holding. Engine safety override at $4.96: Quality below floor (1.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.1/10 and A.R:R 9.7:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 3.25; Below-average business quality.
AtaiBeckley is a clinical-stage biopharmaceutical company advancing a diversified pipeline of psychedelic and non-psychedelic mental health treatments, led by in-house candidates VLS-01 (DMT) for treatment-resistant depression and EMP-01 (R-MDMA) for social anxiety disorder,... Read more
Sell if holding. Engine safety override at $4.96: Quality below floor (1.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.1/10 and A.R:R 9.7:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 3.25; Below-average business quality. Chart setup: Golden cross, above all MAs, RSI 69, MACD bullish. Score 4.1/10, moderate confidence.
Passes 8/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news boost analyst 0.60, earnings proximity 38d clear, semi cycle peak clear, materials cycle peak clear). Suitability: speculative.
Recent developments
updated 2026-07-07Recent Developments — AtaiBeckley Inc.
Latest news
- NEWS Jefferies Maintains Buy on AtaiBeckley, Maintains $10 Price Target — benzinga Jul 6, 2026 positive
- NEWS Watching AtaiBeckley; Shares See A Spike In Volume To The Upside, Traders Circulate Unconfirmed Report From M&A Blog Sug — benzinga Jul 6, 2026 positive
- NEWS AtaiBeckley Completes Patient Dosing In Depression Drug Trial, Expects Depression Treatment Trial Data In Late 2026 — benzinga Jul 6, 2026 positive
- NEWS AtaiBeckley To Join The Russell 2000 And Russell 3000 Indexes, Effective June 29 — benzinga Jun 25, 2026 positive
- NEWS HC Wainwright & Co. Reiterates Buy on AtaiBeckley, Maintains $25 Price Target — benzinga Jun 8, 2026 positive
Generated 2026-07-07T11:31:43Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
5 floor-breakers·1 ceiling hit
Revenue shrinking — -38.7% YoY. Growth thesis broken unless recovery story develops.static
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Volatile — 8.1% daily ATR makes tight stops impractical. Position-size conservatively.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $4.96: Quality below floor (1.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.1/10 and A.R:R 9.7:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 3.25; Below-average business quality. Chart setup: Golden cross, above all MAs, RSI 69, MACD bullish. Prior stop was $4.61. Score 4.1/10, moderate confidence.
Take-profit target: $12.18 (+145.6% upside). Prior stop was $4.61. Stop-loss: $4.61.
Quality below floor (1.4 < 4.0); Value-trap signals (2/5): Margin compression (op margin -11.5%), High leverage (D/E 33.0).
AtaiBeckley Inc. trades at a P/E of N/A (forward -11.4). TrendMatrix value score: 9.0/10. Verdict: Sell.
20 analysts cover ATAI with a consensus score of 4.2/5. Average price target: $14.
What does AtaiBeckley Inc. do?AtaiBeckley is a clinical-stage biopharmaceutical company advancing a diversified pipeline of psychedelic and...
AtaiBeckley is a clinical-stage biopharmaceutical company advancing a diversified pipeline of psychedelic and non-psychedelic mental health treatments, led by in-house candidates VLS-01 (DMT) for treatment-resistant depression and EMP-01 (R-MDMA) for social anxiety disorder, alongside a roughly one-third stake in Beckley Psytech (BPL-003, ELE-101) and a 51.9% stake in Recognify Life Sciences (RL-007 for cognitive impairment in schizophrenia). The company has no approved products and reported a $149.3 million net loss for 2024 against $17.5 million of cash as of December 31, 2024.